Medicenna Provides Update on its Presentations at the 2024 ASCO Annual MeetingGlobeNewsWire • 05/13/24
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital ManagementGlobeNewsWire • 04/30/24
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital ManagementGlobeNewsWire • 04/26/24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual MeetingGlobeNewsWire • 04/24/24
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)GlobeNewsWire • 04/10/24
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)GlobeNewsWire • 04/09/24
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingGlobeNewsWire • 03/06/24
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate UpdateGlobeNewsWire • 02/14/24
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsGlobeNewsWire • 02/13/24
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabGlobeNewsWire • 01/09/24
All You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyZacks Investment Research • 11/20/23
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncologyGlobeNewsWire • 11/17/23
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsGlobeNewsWire • 11/14/23
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingGlobeNewsWire • 11/09/23
Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/09/22
Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/12/21
Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Medicenna Therapeutics Corp.'s (MDNA) CEO Dr. Fahar Merchant on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/28/21